Abstract
One of the critical issues in Parkinson disease (PD) research is the identity of the specific toxic, pathogenic moiety. In PD, mutations in alpha-synuclein (αsyn) or multiplication of the SNCA gene encoding αsyn, result in a phenotype of cellular inclusions, cell death, and brain dysfunction. While the historical point of view has been that the macroscopic aggregates containing αsyn are the toxic species, in the last several years evidence has emerged that suggests instead that smaller soluble species - likely oligomers containing misfolded αsyn - are actually the toxic moiety and that the fibrillar inclusions may even be a cellular detoxification pathway and less harmful. If soluble misfolded species of αsyn are the toxic moieties, then cellular mechanisms that degrade misfolded αsyn would be neuroprotective and a rational target for drug development. In this review we will discuss the fundamental mechanisms underlying αsyn toxicity including oligomer formation, oxidative stress, and degradation pathways and consider rational therapeutic strategies that may have the potential to prevent or halt αsyn induced pathogenesis in PD.
Keywords: Alpha-synuclein, Parkinson's Disease, Chaperones, Oligomers, Heat shock proteins, oxidative stress, Degradation, Neurodegeneration, AMPA, MPTP, PINK1, Geldanamycin, Gene therapy, CHIP, Chaperone-mediated autophagy
CNS & Neurological Disorders - Drug Targets
Title: Drug Targets from Genetics: Alpha-Synuclein
Volume: 10 Issue: 6
Author(s): Karin M. Danzer and Pamela J. McLean
Affiliation:
Keywords: Alpha-synuclein, Parkinson's Disease, Chaperones, Oligomers, Heat shock proteins, oxidative stress, Degradation, Neurodegeneration, AMPA, MPTP, PINK1, Geldanamycin, Gene therapy, CHIP, Chaperone-mediated autophagy
Abstract: One of the critical issues in Parkinson disease (PD) research is the identity of the specific toxic, pathogenic moiety. In PD, mutations in alpha-synuclein (αsyn) or multiplication of the SNCA gene encoding αsyn, result in a phenotype of cellular inclusions, cell death, and brain dysfunction. While the historical point of view has been that the macroscopic aggregates containing αsyn are the toxic species, in the last several years evidence has emerged that suggests instead that smaller soluble species - likely oligomers containing misfolded αsyn - are actually the toxic moiety and that the fibrillar inclusions may even be a cellular detoxification pathway and less harmful. If soluble misfolded species of αsyn are the toxic moieties, then cellular mechanisms that degrade misfolded αsyn would be neuroprotective and a rational target for drug development. In this review we will discuss the fundamental mechanisms underlying αsyn toxicity including oligomer formation, oxidative stress, and degradation pathways and consider rational therapeutic strategies that may have the potential to prevent or halt αsyn induced pathogenesis in PD.
Export Options
About this article
Cite this article as:
M. Danzer Karin and J. McLean Pamela, Drug Targets from Genetics: Alpha-Synuclein, CNS & Neurological Disorders - Drug Targets 2011; 10 (6) . https://dx.doi.org/10.2174/187152711797247867
DOI https://dx.doi.org/10.2174/187152711797247867 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research Discovery of Cationic Polymers for Non-Viral Gene Delivery Using Combinatorial Approaches
Combinatorial Chemistry & High Throughput Screening To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Recent Evidence of the Regulatory Role of PPARs in Neural Stem Cells and Their Underlying Mechanisms for Neuroprotective Effects
Current Stem Cell Research & Therapy Ethnobotanical Treatment Strategies Against Alzheimers Disease
Current Alzheimer Research Beta-Amyloid, Oxidative Stress and Down Syndrome
Current Alzheimer Research Targeting Schistosome Histone Modifying Enzymes for Drug Development
Current Pharmaceutical Design GSK-3 Inhibitors as New Leads to Treat Type-II Diabetes
Current Drug Targets Classes of Sigma2 (σ2) Receptor Ligands: Structure Affinity Relationship (SAfiR) Studies and Antiproliferative Activity
Current Pharmaceutical Design Carbohydrate Mimotopes in the Rational Design of Cancer Vaccines
Current Topics in Medicinal Chemistry Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets QSAR Approaches Applied to Antidepressants Induced Neurogenesis - in vivo and in silico Applications
Mini-Reviews in Medicinal Chemistry Microdialysis: A Technique for Pharmacokinetic-Pharmacodynamic Studies of Oncological Drugs
Current Pharmaceutical Biotechnology Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Fatty Acid Synthase: A Target for the Reversal of Liver Steatosis
Current Enzyme Inhibition Alzheimers Disease and n-3 Polyunsaturated Fatty Acids: Beneficial Effects and Possible Molecular Pathways Involved
Current Signal Transduction Therapy